Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$54.26 ▲ +0.15
(+0.28%)
MKT CAP: $5.25B • VOL: 1.31M
52W L $44 52W H $65
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$46
MEDIAN
$61
MEAN
$62
HIGH
$74
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE CRSP TAPE
CRSP // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $65.65 | $62.40 | 2025-02-14 | $49.38 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $68.37 | $64.03 | 2025-02-06 | $51.00 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $61.86 | $59.69 | 2025-01-29 | $52.09 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $55.35 | — | 2025-01-17 | $53.17 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $47.75 | $51.55 | 2025-01-09 | $48.29 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $64.57 | $56.43 | 2024-12-18 | $47.21 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $52.63 | $54.80 | 2024-12-04 | $50.46 | -4.3% | 48% | C |